Efficacy of WT1 and PR1 peptide vaccination for patients with low risk myeloid malignancies
Latest Information Update: 18 Sep 2021
At a glance
- Drugs INNO 305; PR1 peptide vaccine; Sargramostim
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2021 Biomarkers information updated
- 18 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 18 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.